Table 3 Process suitability and matrix influence for PMX53 and PMX205 determination.

From: Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice

 

Spiked conc. plasma (ng/ml) & tissue (ng/g)

Process efficiency

Plasma

Brain

Spinal cord

Recovery

Extraction efficiency

Matrix effect

Recovery

Extraction efficiency

Matrix effect

Recovery

Extraction efficiency

Matrix effect

(mean ± SD%)

(mean ± SD%)

(mean ± SD%)

(mean ± SD%)

(mean ± SD%)

(mean ± SD%)

(mean ± SD%)

(mean ± SD%)

(mean ± SD%)

(mean ± SD%)

PMX53

LQC (6.25)

98.1 ± 2.4

95.9 ± 0.4

95.3 ± 2.3

0.6 ± 0.5

97.2 ± 1.4

96.3 ± 3.3

−2.8 ± 4.8

96.3 ± 1.4

97.1 ± 1.4

2.2 ± 0.1

MQC (25)

94.2 ± 2.4

94.7 ± 2.3

97.2 ± 2.3

2.6 ± 0.5

99.1 ± 3.4

98.2 ± 3.9

−0.85 ± 4.9

95.1 ± 1.4

99.1 ± 1.5

4.24 ± 1

HQC (200)

98.2 ± 0.6

99.1 ± 1.9

98.1 ± 1.9

−0.94 ± 0.8

85.2 ± 0.4

84.6 ± 0.4

−0.67 ± 0.7

99.1 ± 1.5

98.3 ± 1.5

−0.7 ± 1.1

PMX205

LQC (6.25)

94.1 ± 0.7

92.5 ± 0.7

95.1 ± 0.8

2.4 ± 0.2

85.9 ± 1.1

87.4 ± 0.9

−2.0 ± 3.2

93.2 ± 6.2

95.4 ± 1.7

3.6 ± 0.5

MQC (25)

93.4 ± 1.1

93.9 ± 2.2

96.5 ± 2.2

2.6 ± 0.5

87.1 ± 1.7

86.2 ± 1.6

−0.8 ± 4.5

94.1 ± 5.5

98.1 ± 5.8

4.2 ± 0.9

HQC (200)

96.1 ± 0.9

90.6 ± 1.2

87.5 ± 1.2

−3.5 ± 3.7

97.1 ± 5.1

99.5 ± 5.2

3.5 ± 1.2

93.8 ± 4.1

90.4 ± 3.9

3.6 ± 3.7

  1. Recoveries, extraction efficiencies and matrix effect of the bioanalytical method for PMX53 and PMX205 determination in mice plasma, brain & spinal cord (n = 3, 6 replicates per day).